4 september 2016: lees ook dit artikel: 

https://kanker-actueel.nl/NL/radium-223-samen-met-abiraterone-of-enzalutamine-geeft-langere-overall-overleving-dan-alleen-radium-223-of-alleen-andere-behandelingen-bij-uitgezaaide-vergevorderde-prostaatkanker.html

28 juli 2011: Bron: American Journal of Health-System Pharmacy

Denosumab bljkt een uitstekend middel om het proces van osteoporosis bij vrouwen na de overgang tegen te gaan. Uit een grote fase III studie blijkt dat Denosumab de vermindering van de botdichtheid en daaruit volgende botbreuken en heupbreuken tegengaat. Meer dan 10.000 vrouwen na de overgang met al symptomen en klachten van beginnende osteoporosis werden onderzocht in een gerandomiseerde fase III studie. En daaruit bleek dat denosumab deze klachten vermindert en ook ervoor zorgt dat er minder botbreuken en heupbreuken optreden. Hier het abstract van de studie, maar als u hier klikt kunt u het volledige studierapport tegen betaling inzien.

Denosumab has been shown to decrease bone resorption; increase BMD at all skeletal sites measured; and significantly reduce rates of vertebral, nonvertebral, and hip fractures in postmenopausal women with osteoporosis. Denosumab appears to have a favorable risk:benefit profile and provides a new treatment option for many patients in this population.

Bron: American Journal of Health-System Pharmacy

Denosumab for treatment of postmenopausal osteoporosis

  1. Mona Chitre,
  2. David Shechter and
  3. Andreas Grauer

+ Author Affiliations

  1. Mona Chitre, Pharm.D., CGP, is Director, Clinical Services, Strategy and Policy, Excellus BlueCross BlueShield, Rochester, NY. David Shechter, Ph.D., is Senior Manager, Scientific Affairs; and Andreas Grauer, M.D., is Executive Medical Director, Global Development, Amgen Inc., Thousand Oaks, CA
  1. Address correspondence to Dr. Chitre at Excellus BlueCross BlueShield, 165 Court Street, Rochester, NY 14647 (mona.chitre@flrx.com).

Abstract

Purpose The pharmacologic properties, clinical efficacy, and safety profile of the injectable agent denosumab for the treatment of postmenopausal women with osteoporosis are reviewed.

Summary Denosumab, a human monoclonal antibody that targets a key protein mediator of bone resorption, was approved by the Food and Drug Administration in June 2010 for the treatment of postmenopausal women with osteoporosis who are at high risk for fracture, including “patients who have failed or are intolerant to other available osteoporosis therapy.” Available in a 60-mg prefilled syringe, denosumab should be administered subcutaneously by a health care professional at six-month intervals. In Phase III clinical efficacy trials involving nearly 10,000 postmenopausal women, the use of denosumab was associated with a number of significant benefits: reduced bone resorption, increased bone mass, and reduced rates of vertebral, nonvertebral, and hip fractures. Results of two comparison studies indicated that denosumab therapy increased bone mineral density (BMD) at various skeletal sites to a significantly greater extent than alendronate therapy. In the largest clinical trial of the drug to date, adverse effects occurring significantly more often with denosumab versus placebo included eczema-related effects and cellulitis; long-term safety evaluations are ongoing.

Conclusion Denosumab has been shown to decrease bone resorption; increase BMD at all skeletal sites measured; and significantly reduce rates of vertebral, nonvertebral, and hip fractures in postmenopausal women with osteoporosis. Denosumab appears to have a favorable risk:benefit profile and provides a new treatment option for many patients in this population.


Plaats een reactie ...

Reageer op "Denosumab blijkt een uitstekend en effectief middel om proces van osteoporosis (botdichtheid, botbreuken) tegen te gaan bij vrouwen na de overgang met al klachten van osteoporosis"


Gerelateerde artikelen
 

Gerelateerde artikelen

Denosumab iets effectiever >> Denosumab blijkt effectief >> Denosumab lijkt veiliger met >> Denosumab blijkt een uitstekend >> Denosumab geeft prostaatkankerpatienten >>